ARIXTRA
Drug
Mylan Inc.
Total Payments
$800,000
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $600,000 | 1 | 0 |
| 2021 | $200,000 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $800,000 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Retrospective Patient Level Data Collection for Subjects in FondaKIDS III Study | Mylan Inc. | $800,000 | 0 |
Top Doctors Receiving Payments for ARIXTRA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $800,000 | 2 |
Ad
Manufacturing Companies
- Mylan Inc. $800,000
Product Information
- Type Drug
- Total Payments $800,000
- Total Doctors 0
- Transactions 2
About ARIXTRA
ARIXTRA is a drug associated with $800,000 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Mylan Inc..
Payment data is available from 2021 to 2022. In 2022, $600,000 was paid across 1 transactions to 0 doctors.
The most common payment nature for ARIXTRA is "Unspecified" ($800,000, 100.0% of total).
ARIXTRA is associated with 1 research study, including "Retrospective Patient Level Data Collection for Subjects in FondaKIDS III Study" ($800,000).